Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid
Despite the clinical success in the treatment of several types of cancers, the immune checkpoint inhibitors (ICIs) show limited response rates in cancers with low tumor mutational burden (TMB) and antigenicity. Here, we aim to enhance tumor antigenicity at the protein translation level by using non-...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis Group
2022-12-01
|
| Col·lecció: | OncoImmunology |
| Matèries: | |
| Accés en línia: | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2097460 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|